Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2013/03/23 01:27:00」(JST)

wiki en

"Niacin" redirects here. For the neo-fusion band, see Niacin (band).

Niacin (also known as vitamin B₃, nicotinic acid and vitamin PP) is an organic compound with the formula C₆H₅NO₂ and, depending on the definition used, one of the 40 to 80 essential human nutrients.

Niacin is one of five vitamins (when lacking in human diet) associated with a pandemic deficiency disease: niacin deficiency (pellagra), vitamin C deficiency (scurvy), thiamin deficiency (beriberi), vitamin D deficiency (rickets), vitamin A deficiency (night blindness and other symptoms). Niacin has been used for over 50 years to increase levels of HDL in the blood and has been found to modestly decrease the risk of cardiovascular events in a number of controlled human trials.^[3]

This colorless, water-soluble solid is a derivative of pyridine, with a carboxyl group (COOH) at the 3-position. Other forms of vitamin B₃ include the corresponding amide, nicotinamide ("niacinamide"), where the carboxyl group has been replaced by a carboxamide group (CONH₂), as well as more complex amides and a variety of esters. Nicotinic acid and niacinamide are convertible to each other with steady world demand rising from 8500 tonnes per year in 1980s to 40,000 in recent years^[4].

Niacin cannot be directly converted to nicotinamide, but both compounds could be converted to NAD and NADP in vivo. Nicotinic acid, nicotinamid and tryptophan (via quinoline acid) are co-factors for nicotinamide adenine dinucleotide (NAD) and nicotinamide adenine dinucleotide phosphate (NADP). NAD converts to NADP by phosphorylation using NAD-kinase enzyme. They are coenzyme of various (more than 100) hydrogenases being important in hydrogen transfer almost in every oxidation reduction reaction in the body ^[5]. NAD is important in catabolism of fat, carbohydrate, protein and alcohol as well as cell signaling and DNA repair and NADP mostly in anabolism reaction such as fatty acid and cholesterol synthesis ^[6]. High energy requirements (brain) or high turnover rate (gut, skin) organs are usually the most susceptible to their deficiency ^[7].Although the two are identical in their vitamin activity, nicotinamide does not have the same pharmacological effects (lipid modifying effects) as niacin. Nicotinamide does not reduce cholesterol or cause flushing.^[8] Nicotinamide may be toxic to the liver at doses exceeding 3 g/day for adults.^[9] Niacin is a precursor to NAD+/NADH and NADP+/NADPH, which play essential metabolic roles in living cells.^[10] Niacin is involved in both DNA repair, and the production of steroid hormones in the adrenal gland.

Dietary needs

One recommended daily allowance of niacin is 2–12 mg/day for children, 14 mg/day for women, 16 mg/day for men, and 18 mg/day for pregnant or breast-feeding women.^[11] Tolerable upper intake levels (UL) for adult men and women is considered to be 35 mg/day by the Dietary Reference Intake system to avoid flushing. In general, niacin status is tested through urinary biomarkers,^[12] which are believed to be more reliable than plasma levels.^[13]

Deficiency

Main article: Pellagra

A man with pellagra, which is caused by a chronic lack of vitamin B₃ in the diet

At present, niacin deficiency is sometimes seen in developed countries, and it is usually apparent in conditions of poverty, malnutrition, and chronic alcoholism.^[14] It also tends to occur in areas where people eat maize (corn, the only grain low in digestible niacin) as a staple food. A special cooking technique called nixtamalization is needed to increase the bioavailability of niacin during maize meal/flour production.

Mild niacin deficiency has been shown to slow metabolism, causing decreased tolerance to cold.

Severe deficiency of niacin in the diet causes the disease pellagra, which is characterized by diarrhea, dermatitis, and dementia, as well as “Casal's necklace” lesions on the lower neck, hyperpigmentation, thickening of the skin, inflammation of the mouth and tongue, digestive disturbances, amnesia, delirium, and eventually death, if left untreated.^[15] Common psychiatric symptoms of niacin deficiency include irritability, poor concentration, anxiety, fatigue, restlessness, apathy, and depression.^[15] Studies have indicated that, in patients with alcoholic pellagra, niacin deficiency may be an important factor influencing both the onset and severity of this condition. Patients with alcoholism typically experience increased intestinal permeability, leading to negative health outcomes.

Hartnup’s disease is a hereditary nutritional disorder resulting in niacin deficiency.^[15] This condition was first identified in the 1950s by the Hartnup family in London. It is due to a deficit in the intestines and kidneys, making it difficult for the body to break down and absorb dietary tryptophan. The resulting condition is similar to pellagra, including symptoms of red, scaly rash, and sensitivity to sunlight. Oral niacin is given as a treatment for this condition in doses ranging from 40–200 mg, with a good prognosis if identified and treated early.^[15] Niacin synthesis is also deficient in carcinoid syndrome, because of metabolic diversion of its precursor tryptophan to form serotonin.

Therapeutic effects

In 1955, Altschul et al. (1955)^[16] described niacin as lipid lowering property for the first time that followed by subsequent studies. Niacin is the oldest lipid lowering drug with unique anti atherosclerotic property. It reduces traditional parameters such as low density lipoprotein cholesterol (LDL), very low-density lipoprotein cholesterol (VLDL-C) and triglycerides (TG) but effectively increases high density lipoprotein cholesterol (HDL) ^[17]. Despite the importance of other cardiovascular risk factors, high HDL correlated to lower cardiovascular event independent of LDL reduction^[18]^[19] Other effects include anti-thrombotic and vascular inflammation, improving endothelial function and plaque stability ^[20]. Niacin alone^[21] .or in combination with other lipid lowering agents such as statin ^[22]or ezetimibe ^[23]significantly reduces risk of cardiovascular disease and arthrosclerosis progression^[24]. Niacin therapeutic effect is mostly through its specific G protein coupled receptor (GPR109A and GPR109B) recently named as hydroxyl carboxylic acid (HCA) receptor 2 ^[25]that highly expressed in adipose tissue, spleen, immune cells and keratinocytes but not in other expected organs such as liver, kidney, heart or intestine ^[26]^[27]. GPR109A inhibits cyclic adenosine monophosphate production and thus lipolysis and free fatty acids available for liver to produce TG and VLDL and consequently LDL ^[28]^[29]. Decrase in free fatty acids also suppress hepatic expression of apolipoprotein C3 (APOC3) and PPARg coactivator-1b (PGC-1b) thus increase VLDL turn over and reduce its production ^[30]. It also inhibits diacylglycerol acyltransferase-2 (important hepatic TG synthesis). The mechanism behind increasing HDL is not totally understood but it seems to be done in various ways. Niacin increase apolipoprotein A1 levels due to anti catabolic effects resulting in higher reverse cholesterol transport. It also inhibits HDL hepatic uptake, down regulating production of cholesterol ester transfer protein (CETP) gene^[31]. Finally, it stimulates ABCA1 transporter in monocytes and macrophages and up regulates peroxisome proliferator-activated receptor γ results in reverse cholesterol transport^[32]. Improving vascular endothelial function has been reported in few experiments using niacin. In an experiment on type 2 diabetes, nicotinic acid improved endothelial function comparing with control. Daily dose of 1 g niacin shows significant lipid modifying properties and reach the plateau using 2 grams. GPR109A in immune cells such as monocytes, macrophages, and dendritic cells is responsible for atherosclerosis effects of niacin by reducing the immune cells’ infiltration of vessel wall^[33] ^[34] It also down regulates endothelial adhesion molecules such as vascular cell adhesion molecule 1 (VCAM-1) or of chemokines such as monocyte chemotactic protein 1 (MCP-1) and inflammatory proteins which results in atherosclerotic stabilization and antithrombotic effects ^[35]. The changes in adhesion molecules and chemokines might be through activation of receptor GPR109A on immune cells ^[36]. adipokines are the adipocytes’ produced mediators. Some adipokines such as tumor necrosis factor (TNF)-a, interleukins and chemokines, have pro-inflammatory effect and some others such as adiponectin have anti-inflammatory effect that regulates inflammatory process, decrease vascular progression and atherosclerosis ^[37]^[38]. Nicotinic acid increase adiponectin plasma levels in humans and mice ^[39]^[40]but inhibits pro-inflammatory chemokines such as MCP-1 and fractalkin ^[41]. Other recently explored therapeutic effect of nicotinic acid are neuroprotective and anti-inflammatory effects, beneficial in animal models of arthritis, chronic renal failure or sepsis however more work needed in this area. Following Coronary Drug Project (CDP) as one of the first experiments being done to study long term clinical lipid lowering effect of niacin in 1960’s to early 1970’s, (JAMA, 1975)^[42] many other experiments been done. Their result been summarized in two most recent meta analysis concluded that therapeutic doses of niacin alone or in combination with other lipid modifying agents such as statin reduce cardiovascular event and arthrosclerosis progression significantly ^[43]^[44]. This agrees with current Nation Cholesterol Education Program (NCEP) on high cholesterol treatment. NCEP recommends niacin alone for cardiovascular and atherogenic dyslipidemia in mild or normal LDL levels or in combination for higher LDL levels (NCEP, 2002)^[45]. 1500mg Immediate release niacin daily results in 13% LDL, 20% LP, 10% TG reduction and 19% HDL increase comparing to placebo^[46]. Extended release niacin alone or with anti-flushing agent (laropiprant) shows similar effects ^[47]^[48].

Niacin binds to and stimulates a G-protein-coupled receptor, GPR109A, which causes the inhibition of fat breakdown in adipose tissue.^[49] Nicotinamide does not bind this receptor which explains why it does not affect blood lipid levels. Lipids that are liberated from adipose tissue are normally used to build very-low-density lipoproteins (VLDL) in the liver, which are precursors of low-density lipoprotein (LDL) or "bad" cholesterol. Because niacin blocks the breakdown of fats, it causes a decrease in free fatty acids in the blood and, as a consequence, decreases the secretion of VLDL and cholesterol by the liver.^[50]

By lowering VLDL levels, niacin also increases the level of high-density lipoprotein (HDL) or "good" cholesterol in blood, and therefore it is sometimes prescribed for people with low HDL, who are also at high risk of a heart attack.^[51]^[52]

The ARBITER 6-HALTS study, reported at the 2009 annual meeting of the American Heart Association and in the New England Journal of Medicine^[53] concluded that, when added to statins, 2000 mg/day of extended-release niacin was more effective than ezetimibe (Zetia) in reducing carotid intima-media thickness, a marker of atherosclerosis.^[54] Additionally, a recent meta-analysis covering 11 randomized controlled clinical trials found positive effects of niacin alone or in combination on all cardiovascular events and on atherosclerosis evolution.^[55]

However, a 2011 study (AIM-HIGH) was halted early because patients showed no decrease in cardiovascular events, but did experience an increase in the risk of stroke. These patients already had LDL levels well controlled by a statin drug, and the aim of the study was to evaluate extended-release niacin (2000 mg per day) to see if raising HDL levels had an additional positive effect on risk. In this study, it did not have such an effect, and appeared to increase stroke risk.^[56] The role of niacin in patients whose LDL is not well-controlled (as in the majority of previous studies with niacin) is still under study and debate. However, it does not seem to offer benefits via raising HDL, in patients already lowering LDL by taking a statin.

Niacin Prescriptions

Different Niacin prescriptions are in the market: 1) Immediate release that is quickly absorbed has more flushing effect and less hapatotoxic. 2) Extended release (Niapsen) with more balanced metabolism which absorbs in 8-12 hours and results in less flushing and lower hepatotoxicity. New Niapsen called R-Niapsen has even lower flushing intensity and duration and could be consumed with aspirin. 3) Laropiprant (Merck & Co., Inc.) is another recent niacin formulation with prostaglandin D2 binding capacity that mediated vaso-dilation and reduced flushing up to 73% ^[57] that has been approved in Europe but pending Food and Drug Administration (FDA) approval ^[58]^[59] There are few over-the counter niacin dietary supplements which lack the safety and efficiency FDA regulatory. For example the type “no flush” contains several non convertible niacin compounds with little clinical activity^[60] or “slow release” has higher hepatotoxic activity hence non-prescription niacin is not recommended due to potential harm ^[61].

Toxicity

Pharmacological doses of niacin (1.5 - 6 g per day) lead to side effects that can include dermatological conditions such as skin flushing and itching, dry skin, and skin rashes including eczema exacerbation and acanthosis nigricans. Some of these symptoms are generally related to niacin's role as the rate limiting cofactor in the histidine decarboxylase enzyme which converts l-histidine into histamine.^{[citation needed]} H1 and H2 receptor mediated histamine is metabolized via a sequence of mono (or di-) amine oxidase and COMT into methylhistamine which is then conjugated through the liver's CYP450 pathways. Persistent flushing and other symptoms may indicate deficiencies in one or more of the cofactors responsible for this enzymatic cascade. Gastrointestinal complaints, such as dyspepsia (indigestion), nausea and liver toxicity fulminant hepatic failure, have also been reported. Side effects of hyperglycemia, cardiac arrhythmias and "birth defects in experimental animals" have also been reported.^[62]

Flushing usually lasts for about 15 to 30 minutes, though it can sometimes last up to two hours. It is sometimes accompanied by a prickly or itching sensation, in particular, in areas covered by clothing. Flushing is mediated by prostaglandin E2 and D2 due to GPR109A activation of epidermal langerhans’ cells and keratinocytes^[63]^[64]. Langerhans use cyclooxygenase type 1 (COX-1) for PGE2 production and are more responsible for acute flushing while keratinocutes are COX-2 dependent and are in active continued vaso-dilation^[65]^[66]. To reduce flushing many studies focused on altering or blocking the prostaglandin mediated pathway^[67]. This effect is mediated by GPR109A-mediated prostaglandin release from the Langerhans cells of the skin and can be blocked by taking 300 mg of aspirin half an hour before taking niacin, by taking one tablet of ibuprofen per day or by co-administering the prostaglandin receptor antagonist laropiprant. Taking the niacin with meals also helps reduce this side effect. After several weeks of a consistent dose, most patients no longer flush.^[68] Slow- or "sustained"-release forms of niacin have been developed to lessen these side effects.^[50]^[69] One study showed the incidence of flushing was significantly lower with a sustained release formulation^[70] though doses above 2 g per day have been associated with liver damage, in particular, with slow-release formulations.^[62] Flushing is often thought to involve histamine, but histamine has been shown not to be involved in the reaction.^[71] Prostaglandin (PGD₂) is the primary cause of the flushing reaction, with serotonin appearing to have a secondary role in this reaction.^[71]

Hepatotoxicity is another side effect of niacin. Metabolizing niacin occurs in liver in 2 ways one through conjugation pathway producing nicotinuric acid metabolite related to flushing the other is amidation resulting in NAD production related to hepatotoxicity^[72].

Although high doses of niacin may elevate blood sugar, thereby worsening diabetes mellitus,^[62] recent studies show the actual effect on blood sugar to be only 5–10%. Patients with diabetes who continued to take anti-diabetes drugs containing niacin did not experience major blood glucose changes. Thus looking at the big picture, niacin continues to be recommended as a drug for preventing cardiovascular disease in patients with diabetes.

Hyperuricemia is another side effect of taking high-dose niacin, and may exacerbate gout.^[73]

Niacin in doses used to lower cholesterol levels has been associated with birth defects in laboratory animals, with possible consequences for infant development in pregnant women.^[62]

Niacin, particularly the time-release variety, at extremely high doses can cause acute toxic reactions.^[74] Extremely high doses of niacin can also cause niacin maculopathy, a thickening of the macula and retina, which leads to blurred vision and blindness. This maculopathy is reversible after niacin intake ceases.^[75]

Nicotinamide

Nicotinamide may be obtained from the diet where it is present primarily as NAD+ and NADP+. These are hydrolysed in the intestine and the resulting nicotinamide is absorbed either as such, or following its hydrolysis to nicotinic acid. Nicotinamide is present in nature in only small amounts. In unprepared foods, niacin is present mainly in the form of the cellular pyridine nucleotides NAD and NADP. Enzymatic hydrolysis of the co-enzymes can occur during the course of food preparation. Boiling releases most of the total niacin present in sweet corn as nicotinamide (up to 55 mg/kg).^[76]

Inositol hexanicotinate

One form of dietary supplement is inositol hexanicotinate (IHN), which is inositol that has been esterified with niacin on all six of inositol's alcohol groups. IHN is usually sold as "flush-free" or "no-flush" niacin in units of 250, 500, or 1000 mg/tablets or capsules. It is sold as an over-the-counter formulation, and often is marketed and labeled as niacin, thus misleading consumers into thinking they are getting the active form of the medication. While this form of niacin does not cause the flushing associated with the immediate-release products, the evidence that it has lipid-modifying functions is contradictory, at best. As the clinical trials date from the early 1960s (Dorner, Welsh) or the late 1970s (Ziliotto, Kruse, Agusti), it is difficult to assess them by today's standards.^[77] One of the last of those studies affirmed the superiority of inositol and xantinol esters of nicotinic acid for reducing serum free fatty acid,^[78] but other studies conducted during the same period found no benefit.^[79] Studies explain that this is primarily because "flush-free" preparations do not contain any free nicotinic acid. A more recent placebo-controlled trial was small (n=11/group), but results after three months at 1500 mg/day showed no trend for improvements in total cholesterol, LDL-C, HDL-C or triglycerides.^[80] Thus, so far there is not enough evidence to recommend IHN to treat dyslipidemia. Furthermore, the American Heart Association and the National Cholesterol Education Program both take the position that only prescription niacin should be used to treat dyslipidemias, and only under the management of a physician. The reason given is that niacin at effective intakes of 1500–3000 mg/day can also potentially have severe adverse effects. Thus liver function tests to monitor liver enzymes are necessary when taking therapeutic doses of niacin, including alkaline phosphatase (ALP), aspartate transaminase (AST), and alanine transaminase (ALT).

Biosynthesis and chemical synthesis

Biosynthesis

The liver can synthesize niacin from the essential amino acid tryptophan, requiring 60 mg of tryptophan to make one mg of niacin.^[11] The 5-membered aromatic heterocycle of tryptophan is cleaved and rearranged with the alpha amino group of tryptophan into the 6-membered aromatic heterocycle of niacin. Riboflavin, vitamin B₆ and iron are required in some of the reactions involved in the conversion of tryptophan to NAD.

Several million kilograms of niacin are manufactured each year, starting from 3-methylpyridine.

Receptor

In addition to its effects as NAD and NADP, niacin may have additional effects by receptor activation. The receptor for niacin is a G protein-coupled receptor called HM74A.^[81] It couples to the Gi alpha subunit.^[82]

Food sources

Niacin is found in variety of foods, including liver, chicken, beef, fish, cereal, peanuts and legumes, and is also synthesized from tryptophan, an essential amino acid found in most forms of protein.

Animal products:

liver, heart and kidney (9 – 15 mg niacin per 100 grams)
chicken, chicken breast (6.5 mg)
beef (5 – 6 mg)
fish: tuna, salmon, halibut (2.5 – 13 mg)
eggs (0.1 mg)

Fruits and vegetables:

avocados (1 mg niacin per 100 grams)
dates (2 mg)
tomatoes (0.7 mg)
leaf vegetables (0.3 - 0.4 mg)
broccoli (0.6 mg)
carrots (0.3 - 0.6 mg)
sweet potatoes (0.5 - 0.6 mg)
asparagus (0.4 mg)

Seeds:

nuts (2 mg niacin per 100 grams)
whole grain products (4 - 29.5 mg)
legumes (0.4 – 16 mg)
saltbush seeds

Fungi:

mushrooms, shiitake mushrooms (3.5 – 4 mg niacin per 100 grams)
brewer's yeast (36 mg)

Other:

Monster Energy drink (40 mg per 16 ounces)
Rockstar Energy (100% in the Super Sours flavors)
Red Bull Energy Drink (28 mg per 12 ounces)
Ovaltine (18 mg)
Peanut butter (15 mg)
Tofu
Soy sauce (0.4 mg)
Vegemite (from spent brewer's yeast) (110 mg niacin per 100 grams)

^[83]

History

Niacin was first described by chemist Hugo Weidel in 1873 in his studies of nicotine.^[84] The original preparation remains useful: The oxidation of nicotine using nitric acid.^[85] Niacin was extracted from livers by biochemist Conrad Elvehjem in 1937, who later identified the active ingredient, then referred to as the "pellagra-preventing factor" and the "anti-blacktongue factor."^[86] Soon after, in studies conducted in Alabama and Cincinnati, Dr. Tom Spies found that nicotinic acid cured the sufferers of pellagra.^[87]

When the biological significance of nicotinic acid was realized, it was thought appropriate to choose a name to dissociate it from nicotine, to avoid the perception that vitamins or niacin-rich food contains nicotine, or that cigarettes contain vitamins. The resulting name 'niacin' was derived from nicotinic acid + vitamin.

Carpenter found in 1951 that niacin in corn is biologically unavailable, and can be released only in very alkaline lime water of pH 11.^[88] This process, known as nixtamalization, was discovered by the prehistoric civilizations of Mesoamerica.^[89]

Niacin is referred to as vitamin B₃ because it was the third of the B vitamins to be discovered. It has historically been referred to as "vitamin PP" or "vitamin P-P".

Research

As of August 2008^[update], a combination of niacin with laropiprant is being tested in a clinical trial. Laropiprant reduces facial flushes induced by niacin.^[90]

References

^ "Niacin". DrugBank: a knowledgebase for drugs, drug actions and drug targets. http://www.drugbank.ca/drugs/DB00627. Retrieved 14-January-2012.
^ "Niacin — PubChem Public Chemical Database". The PubChem Project. USA: National Center for Biotechnology Information. http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=938.
^ Bruckert, E; Labreuche, J; Amarenco, P (2010 Jun). "Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis.". Atherosclerosis 210 (2): 353–61. doi:10.1016/j.atherosclerosis.2009.12.023. PMID 20079494.
^ Cantarella, L., A. Gallifuoco, et al. (2011). "High-yield continuous production of nicotinic acid via nitrile hydratase-amidase cascade reactions using cascade CSMRs." Enzyme Microb Technol 48(4-5): 345-350.http://www.ncbi.nlm.nih.gov/pubmed/22112948?dopt=Citation
^ Wan, P., S. Moat, et al. (2011). "Pellagra: a review with emphasis on photosensitivity." Br J Dermatol 164(6): 1188-1200.http://www.ncbi.nlm.nih.gov/pubmed/21128910?dopt=Citation
^ Wan, P., S. Moat, et al. (2011). "Pellagra: a review with emphasis on photosensitivity." Br J Dermatol 164(6): 1188-1200.http://www.ncbi.nlm.nih.gov/pubmed/21128910?dopt=Citation
^ Ishii, N. and Y. Nishihara (1981). "Pellagra among chronic alcoholics: clinical and pathological study of 20 necropsy cases." J Neurol Neurosurg Psychiatry 44(3): 209-215.http://www.ncbi.nlm.nih.gov/pubmed/7229643?dopt=Citation
^ Jaconello P (October 1992). "Niacin versus niacinamide". CMAJ 147 (7): 990. PMC 1336277. PMID 1393911. //www.ncbi.nlm.nih.gov/pmc/articles/PMC1336277/.
^ Knip M, Douek IF, Moore WP, et al. (2000). "Safety of high-dose nicotinamide: a review". Diabetologia 43 (11): 1337–45. doi:10.1007/s001250051536. PMID 11126400.
^ Cox, Michael; Lehninger, Albert L; Nelson, David R. (2000). Lehninger principles of biochemistry. New York: Worth Publishers. ISBN 1-57259-153-6.
^ ^a ^b Jacobson, EL (2007). "Niacin". Linus Pauling Institute. http://lpi.oregonstate.edu/infocenter/vitamins/niacin/. Retrieved 2011-08-08.
^ Institute of Medicine (2006). Dietary Reference Intakes Research Synthesis: Workshop Summary. National Academies Press. p. 37. http://books.nap.edu/openbook.php?record_id=11767&page=37.
^ Jacob RA, Swendseid ME, McKee RW, Fu CS, Clemens RA (April 1989). "Biochemical markers for assessment of niacin status in young men: urinary and blood levels of niacin metabolites". J. Nutr. 119 (4): 591–8. PMID 2522982. http://jn.nutrition.org/cgi/pmidlookup?view=long&pmid=2522982.
^ Pitsavas S, Andreou C, Bascialla F, Bozikas VP, Karavatos A (2004). "Pellagra encephalopathy following B-complex vitamin treatment without niacin". Int J Psychiatry Med 34 (1): 91–5. doi:10.2190/29XV-1GG1-U17K-RGJH. PMID 15242145. http://baywood.metapress.com/link.asp?id=29xv1gg1u17krgjh.
^ ^a ^b ^c ^d Prakash, Ravi; Sachin Gandotra, Lokesh Kumar Singh, Basudeb Das, Anuja Lakra (2008). "Rapid resolution of delusional parasitosis in pellagra with niacin augmentation therapy". General Hospital Psychiatry 30 (6): 581–4. doi:10.1016/j.genhosppsych.2008.04.011. PMID 19061687. http://www.sciencedirect.com/science/article/B6T70-4T24FKB-D/2/f619871a3d1f1d626b775c84523d6d94.
^ Altschul, R., A. Hoffer, et al. (1955). "Influence of nicotinic acid on serum cholesterol in man." Arch Biochem Biophys 54(2): 558-559.http://www.ncbi.nlm.nih.gov/pubmed/14350806?dopt=Citation
^ Villines, T. C., A. S. Kim, et al. (2012). "Niacin: the evidence, clinical use, and future directions." Curr Atheroscler Rep 14(1): 49-59.http://www.ncbi.nlm.nih.gov/pubmed/22037771?dopt=Citation
^ Barter, P., A. M. Gotto, et al. (2007). "HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events." N Engl J Med 357(13): 1301-1310.http://www.ncbi.nlm.nih.gov/pubmed/17898099?dopt=Citation
^ Jafri, H., A. A. Alsheikh-Ali, et al. (2010). "Meta-analysis: statin therapy does not alter the association between low levels of high-density lipoprotein cholesterol and increased cardiovascular risk." Ann Intern Med 153(12): 800-808.http://www.ncbi.nlm.nih.gov/pubmed/21173414?dopt=Citation
^ Wu, B. J., L. Yan, et al. (2010). "Evidence that niacin inhibits acute vascular inflammation and improves endothelial dysfunction independent of changes in plasma lipids." Arterioscler Thromb Vasc Biol 30(5): 968-975.http://www.ncbi.nlm.nih.gov/pubmed/20167660?dopt=Citation
^ Bruckert, E., J. Labreuche, et al. (2010). "Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis." Atherosclerosis 210(2): 353-361.http://www.ncbi.nlm.nih.gov/pubmed/20079494?dopt=Citation
^ Taylor, A. J., H. J. Lee, et al. (2006). "The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3." Curr Med Res Opin 22(11): 2243-2250.http://www.ncbi.nlm.nih.gov/pubmed/17076985?dopt=Citation
^ Taylor, A. J., T. C. Villines, et al. (2009). "Extended-release niacin or ezetimibe and carotid intima-media thickness." N Engl J Med 361(22): 2113-2122.http://www.ncbi.nlm.nih.gov/pubmed/19915217?dopt=Citation
^ Lukasova, M., J. Hanson, et al. (2011). "Nicotinic acid (niacin): new lipid-independent mechanisms of action and therapeutic potentials." Trends Pharmacol Sci 32(12): 700-707.http://www.ncbi.nlm.nih.gov/pubmed/21944259?dopt=Citation
^ Lukasova, M., J. Hanson, et al. (2011). "Nicotinic acid (niacin): new lipid-independent mechanisms of action and therapeutic potentials." Trends Pharmacol Sci 32(12): 700-707.http://www.ncbi.nlm.nih.gov/pubmed/21944259?dopt=Citation
^ Soga, T., M. Kamohara, et al. (2003). "Molecular identification of nicotinic acid receptor." Biochem Biophys Res Commun 303(1): 364-369.http://www.ncbi.nlm.nih.gov/pubmed/12646212?dopt=Citation
^ Wise, A., S. M. Foord, et al. (2003). "Molecular identification of high and low affinity receptors for nicotinic acid." J Biol Chem 278(11): 9869-9874.http://www.ncbi.nlm.nih.gov/pubmed/12522134?dopt=Citation
^ Gille, A., E. T. Bodor, et al. (2008). "Nicotinic acid: pharmacological effects and mechanisms of action." Annu Rev Pharmacol Toxicol 48: 79-106.http://www.ncbi.nlm.nih.gov/pubmed/17705685?dopt=Citation
^ Wanders, D. and R. L. Judd (2011). "Future of GPR109A agonists in the treatment of dyslipidaemia." Diabetes Obes Metab 13(8): 685-691.http://www.ncbi.nlm.nih.gov/pubmed/21418500?dopt=Citation
^ Hernandez, C., M. Molusky, et al. (2010). "Regulation of hepatic ApoC3 expression by PGC-1beta mediates hypolipidemic effect of nicotinic acid." Cell Metab 12(4): 411-419.http://www.ncbi.nlm.nih.gov/pubmed/20889132?dopt=Citation
^ Villines, T. C., A. S. Kim, et al. (2012). "Niacin: the evidence, clinical use, and future directions." Curr Atheroscler Rep 14(1): 49-59.
^ Rubic, T., M. Trottmann, et al. (2004). "Stimulation of CD36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin." Biochem Pharmacol 67(3): 411-419.http://www.ncbi.nlm.nih.gov/pubmed/15037193?dopt=Citation
^ Lukasova, M., C. Malaval, et al. (2011). "Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells." J Clin Invest 121(3): 1163-1173.http://www.ncbi.nlm.nih.gov/pubmed/21317532?dopt=Citation
^ Holzhauser, E., C. Albrecht, et al. (2011). "Nicotinic acid has anti-atherogenic and anti-inflammatory properties on advanced atherosclerotic lesions independent of its lipid-modifying capabilities." J Cardiovasc Pharmacol 57(4): 447-454.http://www.ncbi.nlm.nih.gov/pubmed/21242806?dopt=Citation
^ Wu, B. J., L. Yan, et al. (2010). "Evidence that niacin inhibits acute vascular inflammation and improves endothelial dysfunction independent of changes in plasma lipids." Arterioscler Thromb Vasc Biol 30(5): 968-975.http://www.ncbi.nlm.nih.gov/pubmed/20167660?dopt=Citation
^ Lukasova, M., C. Malaval, et al. (2011). "Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells." J Clin Invest 121(3): 1163-1173.http://www.ncbi.nlm.nih.gov/pubmed/21317532?dopt=Citation
^ Benjo, A. M., R. C. Maranhao, et al. (2006). "Accumulation of chylomicron remnants and impaired vascular reactivity occur in subjects with isolated low HDL cholesterol: effects of niacin treatment." Atherosclerosis 187(1): 116-122.http://www.ncbi.nlm.nih.gov/pubmed/16458316?dopt=Citation
^ Gustafson, B. (2010). "Adipose tissue, inflammation and atherosclerosis." J Atheroscler Thromb 17(4): 332-341.http://www.ncbi.nlm.nih.gov/pubmed/20124732?dopt=Citation
^ Plaisance, E. P., M. Lukasova, et al. (2009). "Niacin stimulates adiponectin secretion through the GPR109A receptor." Am J Physiol Endocrinol Metab 296(3): E549-558.http://www.ncbi.nlm.nih.gov/pubmed/19141678?dopt=Citation
^ Westphal, S. and C. Luley (2008). "Preferential increase in high-molecular weight adiponectin after niacin." Atherosclerosis 198(1): 179-183.http://www.ncbi.nlm.nih.gov/pubmed/17996241?dopt=Citation
^ Digby, J. E., E. McNeill, et al. (2010). "Anti-inflammatory effects of nicotinic acid in adipocytes demonstrated by suppression of fractalkine, RANTES, and MCP-1 and upregulation of adiponectin." Atherosclerosis 209(1): 89-95.http://www.ncbi.nlm.nih.gov/pubmed/19781706?dopt=Citation
^ JAMA. (1975). "Clofibrate and niacin in coronary heart disease." JAMA 231(4): 360-381.
^ Bruckert, E., J. Labreuche, et al. (2010). "Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis." Atherosclerosis 210(2): 353-361.http://www.ncbi.nlm.nih.gov/pubmed/20079494?dopt=Citation
^ Duggal, J. K., M. Singh, et al. (2010). "Effect of niacin therapy on cardiovascular outcomes in patients with coronary artery disease." J Cardiovasc Pharmacol Ther 15(2): 158-166.http://www.ncbi.nlm.nih.gov/pubmed/20208032?dopt=Citation
^ NCEP. (2002). "Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report." Circulation 106(25): 3143-3421.
^ H., P. Alagona, et al. (1998). "Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia." Metabolism 47(9): 1097-1104.http://www.ncbi.nlm.nih.gov/pubmed/9751239?dopt=Citation
^ Bays, H., A. Shah, et al. (2011). "Extended-release niacin/laropiprant lipid-altering consistency across patient subgroups." Int J Clin Pract 65(4): 436-445.http://www.ncbi.nlm.nih.gov/pubmed/21401833?dopt=Citation
^ McKenney, J., H. Bays, et al. (2010). "Safety of extended-release niacin/laropiprant in patients with dyslipidemia." J Clin Lipidol 4(2): 105-112 e101.http://www.ncbi.nlm.nih.gov/pubmed/21122637?dopt=Citation
^ Gille A, Bodor ET, Ahmed K, Offermanns S (2008). "Nicotinic acid: pharmacological effects and mechanism of action". Annu Rev Pharmacol Toxicol 48: 79–106. doi:10.1146/annurev.pharmtox.48.113006.094746. PMID 17705685.
^ ^a ^b Katzung, Bertram G. (2006). Basic and clinical pharmacology. New York: McGraw-Hill Medical Publishing Division. ISBN 0-07-145153-6. http://www.medicinenet.com/niacin/article.htm.
^ McGovern ME (2005). "Taking aim at HDL-C. Raising levels to reduce cardiovascular risk". Postgrad Med 117 (4): 29–30, 33–5, 39 passim. doi:10.3810/pgm.2005.04.1610. PMID 15842130.
^ Canner PL, Berge KG, Wenger NK, et al. (1986). "Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin". J. Am. Coll. Cardiol. 8 (6): 1245–55. doi:10.1016/S0735-1097(86)80293-5. PMID 3782631.
^ Taylor AJ, Villines TC, Stanek EJ, et al. (November 2009). "Extended-release niacin or ezetimibe and carotid intima-media thickness". N. Engl. J. Med. 361 (22): 2113–22. doi:10.1056/NEJMoa0907569. PMID 19915217.
^ Singer, Natasha (November 15, 2009). "Study Raises Questions About Cholesterol Drug’s Benefit". The New York Times. Retrieved November 16, 2009.
^ Bruckert, E; Labreuche, J; Amarenco, P (2010). "Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis". Atherosclerosis 210 (2): 353–61. doi:10.1016/j.atherosclerosis.2009.12.023. PMID 20079494.
^ Aim-High, I.; Boden, W. E.; Probstfield, J. L.; Anderson, T.; Chaitman, B. R.; Desvignes-Nickens, P.; Koprowicz, K.; McBride, R. et al. (2011). "Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy". New England Journal of Medicine 365 (24): 2255–2267. doi:10.1056/NEJMoa1107579. PMID 22085343. edit
^ Lai, E., I. De Lepeleire, et al. (2007). "Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D2 receptor subtype 1." Clin Pharmacol Ther 81(6): 849-857.http://www.ncbi.nlm.nih.gov/pubmed/17392721?dopt=Citation
^ Kamanna, V. S., A. Vo, et al. (2008). "Nicotinic acid: recent developments." Curr Opin Cardiol 23(4): 393-398.http://www.ncbi.nlm.nih.gov/pubmed/18520725?dopt=Citation.
^ Villines, T. C., A. S. Kim, et al. (2012). "Niacin: the evidence, clinical use, and future directions." Curr Atheroscler Rep 14(1): 49-59.http://www.ncbi.nlm.nih.gov/pubmed/22037771?dopt=Citation
^ Norris, R. B. (2006). ""Flush-free niacin": dietary supplement may be "benefit-free"." Prev Cardiol 9(1): 64-65.http://www.ncbi.nlm.nih.gov/pubmed/16407706?dopt=Citation
^ Villines, T. C., A. S. Kim, et al. (2012). "Niacin: the evidence, clinical use, and future directions." Curr Atheroscler Rep 14(1): 49-59.http://www.ncbi.nlm.nih.gov/pubmed/22037771?dopt=Citation
^ ^a ^b ^c ^d Keith Parker; Laurence Brunton; Goodman, Louis Sanford; Lazo, John S.; Gilman, Alfred (2006). Goodman & Gilman's the pharmacological basis of therapeutics. New York: McGraw-Hill. ISBN 0-07-142280-3.
^ Benyo, Z., A. Gille, et al. (2005). "GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing." J Clin Invest 115(12): 3634-3640.http://www.ncbi.nlm.nih.gov/pubmed/16322797?dopt=Citation
^ Benyo, Z., A. Gille, et al. (2006). "Nicotinic acid-induced flushing is mediated by activation of epidermal langerhans cells." Mol Pharmacol 70(6): 1844-1849.http://www.ncbi.nlm.nih.gov/pubmed/17008386?dopt=Citation
^ Hanson, J., A. Gille, et al. (2010). "Nicotinic acid- and monomethyl fumarate-induced flushing involves GPR109A expressed by keratinocytes and COX-2-dependent prostanoid formation in mice." J Clin Invest 120(8): 2910-2919.http://www.ncbi.nlm.nih.gov/pubmed/20664170?dopt=Citation
^ Maciejewski-Lenoir, D., J. G. Richman, et al. (2006). "Langerhans cells release prostaglandin D2 in response to nicotinic acid." J Invest Dermatol 126(12): 2637-2646.http://www.ncbi.nlm.nih.gov/pubmed/17008871?dopt=Citation
^ Kamanna, V. S. and M. L. Kashyap (2008). "Mechanism of action of niacin." Am J Cardiol 101(8A): 20B-26B. Nicotinic acid (niacin) has long been used for the treatment of lipid disorders and cardiovascular http://www.ncbi.nlm.nih.gov/pubmed/18375237?dopt=Citation
^ "Guidelines for Niacin Therapy For the Treatment of Elevated Lipoprotein a (Lpa)". Rush Hemophilia & Thrombophilia Center. August 15, 2002, Revised July 27, 2005. http://www.rush.edu/Rush_Document/Niacin%20therapy%20for%20elevated%20Lpa,0.pdf. Retrieved 20 November 2009. "facial flushing is a common side effect of niacin therapy that usually subsides after several weeks of consistent niacin use"
^ Barter, P (2006). "Options for therapeutic intervention: How effective are the different agents?". European Heart Journal Supplements 8 (F): F47–F53. doi:10.1093/eurheartj/sul041.
^ Chapman MJ, Assmann G, Fruchart JC, Shepherd J, Sirtori C (2004). "Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid—a position paper developed by the European Consensus Panel on HDL-C". Curr Med Res Opin 20 (8): 1253–68. doi:10.1185/030079904125004402. PMID 15324528.
^ ^a ^b Papaliodis D, Boucher W, Kempuraj D, Michaelian M, Wolfberg A, House M, Theoharides TC (December 2008). "Niacin-induced "Flush" Involves Release of Prostaglandin D2 from Mast Cells and Serotonin from Platelets: Evidence from Human Cells in Vitro and an Animal Model". J Pharmacol Exp Ther 327 (3): 665–72. doi:10.1124/jpet.108.141333. PMID 18784348. http://jpet.aspetjournals.org/cgi/pmidlookup?view=long&pmid=18784348.
^ Gille, A., E. T. Bodor, et al. (2008). "Nicotinic acid: pharmacological effects and mechanisms of action." Annu Rev Pharmacol Toxicol 48: 79-106.http://www.ncbi.nlm.nih.gov/pubmed/17705685?dopt=Citation
^ Capuzzi DM, Morgan JM, Brusco OA, Intenzo CM (2000). "Niacin dosing: relationship to benefits and adverse effects". Curr Atheroscler Rep 2 (1): 64–71. doi:10.1007/s11883-000-0096-y. PMID 11122726.
^ Mittal MK, Florin T, Perrone J, Delgado JH, Osterhoudt KC (2007). "Toxicity from the use of niacin to beat urine drug screening". Ann Emerg Med 50 (5): 587–90. doi:10.1016/j.annemergmed.2007.01.014. PMID 17418450.
^ Gass JD (2003). "Nicotinic acid maculopathy. 1973". Retina (Philadelphia, Pa.) 23 (6 Suppl): 500–10. PMID 15035390.
^ http://www.efsa.europa.eu/en/scdocs/doc/ans_ej949_Inositol_hexanicotinate_op_en_REV.pdf
^ Taheri, R (2003-01-15). "No-Flush Niacin for the Treatment of Hyperlipidemia". Medscape. http://www.medscape.com/viewarticle/447528. Retrieved 2008-03-31.
^ Kruse W, Kruse W, Raetzer H, Heuck CC, Oster P, Schellenberg B, Schlierf G (1979). "Nocturnal inhibition of lipolysis in man by nicotinic acid and derivatives". European Journal of Clinical Pharmacology 16 (1): 11–15. doi:10.1007/BF00644960. PMID 499296.
^ Meyers CD, Carr MC, Park S, Brunzell JD (2003). "Varying cost and free nicotinic acid content in over-the-counter niacin preparations for dyslipidemia". Annals of Internal Medicine 139 (12): 996–1002. doi:10.7326/0003-4819-139-12-200312160-00009. PMID 14678919. http://www.annals.org/content/139/12/996.full.pdf+html.
^ Benjó AM, Maranhão RC, Coimbra SR, Andrade AC, Favarato D, Molina MS, Brandizzi LI, da Luz PL (2006). "Accumulation of chylomicron remnants and impaired vascular reactivity occur in subjects with isolated low HDL cholesterol: effects of niacin treatment". Atherosclerosis 187 (1): 116–122. doi:10.1016/j.atherosclerosis.2005.08.025. PMID 16458316.
^ Zhang Y, Schmidt RJ, Foxworthy P, et al. (2005). "Niacin mediates lipolysis in adipose tissue through its G-protein coupled receptor HM74A". Biochem. Biophys. Res. Commun. 334 (2): 729–32. doi:10.1016/j.bbrc.2005.06.141. PMID 16018973.
^ Zellner C, Pullinger CR, Aouizerat BE, et al. (2005). "Variations in human HM74 (GPR109B) and HM74A (GPR109A) niacin receptors". Hum. Mutat. 25 (1): 18–21. doi:10.1002/humu.20121. PMID 15580557.
^ "Food Data Chart - Niacin". http://www.healthyeatingclub.com/info/books-phds/books/foodfacts/html/data/data4c.html. Retrieved 7 September 2012.
^ Weidel, H (1873). "Zur Kenntniss des Nicotins". Justus Liebig's Annalen der Chemie und Pharmacie 165 (2): 330–349. doi:10.1002/jlac.18731650212.
^ Samuel M. McElvain (1941), "Nicotinic Acid", Org. Synth., http://www.orgsyn.org/orgsyn/orgsyn/prepContent.asp?prep=CV1P0385.pdf; Coll. Vol. 1: 385
^ Elvehjem CA, Madden RJ, Strongandd FM, Woolley DW (1938). "The isolation and identification of the anti-blacktongue factor J" (PDF). J. Biol. Chem. 123 (1): 137–149. http://www.jbc.org/content/123/1/137.full.pdf.
^ Dr. Joseph Goldberger and the war on Pellagra - Office of NIH History
^ LAGUNA J, CARPENTER KJ (September 1951). "Raw versus processed corn in niacin-deficient diets". J. Nutr. 45 (1): 21–8. PMID 14880960. http://jn.nutrition.org/cgi/pmidlookup?view=long&pmid=14880960.
^ "Vitamin B3". University of Maryland Medical Center. 2002-01-04. http://www.umm.edu/altmed/articles/vitamin-b3-000335.htm. Retrieved 2008-03-31.
^ Paolini JF, Bays HE, Ballantyne CM, et al. (November 2008). "Extended-release niacin/laropiprant: reducing niacin-induced flushing to better realize the benefit of niacin in improving cardiovascular risk factors". Cardiol Clin 26 (4): 547–60. doi:10.1016/j.ccl.2008.06.007. PMID 19031552.

External links

Niacin bound to proteins in the PDB

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 成人における禁煙のための薬物療法 pharmacotherapy for smoking cessation in adults
2. ニコチンの心血管系への影響 cardiovascular effects of nicotine
3. 成人における禁煙マネージメントの概要 overview of smoking cessation management in adults
4. 禁煙の利益とリスク benefits and risks of smoking cessation
5. 統合失調症と物質使用障害の併発に対する治療 treatment of co occurring schizophrenia and substance use disorder

English Journal

Does denture-wearing status in edentulous South Korean elderly persons affect their nutritional intakes?

Han SY1, Kim CS1.
Gerodontology.Gerodontology.2016 Jun;33(2):169-76. doi: 10.1111/ger.12125. Epub 2014 Mar 19.
OBJECTIVE: The aim of this cross-sectional study was to determine whether denture-wearing status in edentulous South Korean elders affected their nutritional intakes, using the 2008-2010 data from the Korean National Health and Nutrition Examination Survey (KNHANES).BACKGROUND: Good nutritional stat
PMID 24641726

Dietary Nutrient Intake in School-Aged Children With Heavy Prenatal Alcohol Exposure.

Nguyen TT1,2, Risbud RD3, Chambers CD4,5, Thomas JD3.
Alcoholism, clinical and experimental research.Alcohol Clin Exp Res.2016 May;40(5):1075-82. doi: 10.1111/acer.13035. Epub 2016 Mar 25.
BACKGROUND: Nutrition is an important factor that affects brain development. Nutritional deficiencies can exacerbate alcohol's damaging effects. Conversely, nutritional supplementation can serve a protective role against alcohol damage and may prove to be a worthwhile intervention strategy. This stu
PMID 27012806

Niacin and olive oil promote skewing to the M2 phenotype in bone marrow-derived macrophages of mice with metabolic syndrome.

Montserrat-de la Paz S1, Naranjo MC1, Lopez S1, Abia R1, Muriana FJ1, Bermudez B2.
Food & function.Food Funct.2016 Apr 26. [Epub ahead of print]
Metabolic syndrome (MetS) is associated with obesity, dyslipemia, type 2 diabetes and chronic low-grade inflammation. The aim of this study was to determine the role of high-fat low-cholesterol diets (HFLCDs) rich in SFAs (HFLCD-SFAs), MUFAs (HFLCD-MUFAs) or MUFAs plus omega-3 long-chain PUFAs (HFLC
PMID 27116638

Japanese Journal

Structural, Electronic, and Magnetic Properties of Novel Spin-Crossover Complex : Fe(butyl nicotinate)₂[Au(CN)₂]₂

Ueno Shoutaro,Kawasaki Takeshi,Okabayashi Jun [他]
Bulletin of the Chemical Society of Japan 88(4), 551-553, 2015-04
NAID 40020428855

Structural, Electronic, and Magnetic Properties of Novel Spin-Crossover Complex: Fe(butyl nicotinate)2[Au(CN)2]2

Ueno Shoutaro,Kawasaki Takeshi,Okabayashi Jun,Kitazawa Takafumi
Bulletin of the Chemical Society of Japan 88(4), 551-553, 2015
… We have synthesized a novel bilayered Hofmann-type 2D network complex Fe(butyl nicotinate)2[Au(CN)2]2 (I). …
NAID 130005064977

Structural, Electronic, and Magnetic Properties of Novel Spin Crossover Complex: Fe(butyl-nicotinate)2[Au(CN)2]2

Ueno Shoutaro,Kawasaki Takeshi,Okabayashi Jun,Kitazawa Takafumi
Bulletin of the Chemical Society of Japan advpub(0), 2015
… We have synthesized a novel bilayered Hofmann-type 2D network complex Fe(butyl-nicotinate)2[Au(CN)2]2 (I). …
NAID 130004801862

Related Pictures

Chromium Nicotinate Complex, 60 Vcaps First, Methyl Nicotinate : Methyl nicotinate 99% | Sigma-Aldrich /Nicotinate de méthyle - tube de 80g Inositol Nicotinate + Cr 60c Medication: HEPARIN–BENZYL NICOTINATE Nicotinate+products

★リンクテーブル★

リンク元	「ニコチン酸」「ニコチン酸塩」
拡張検索	「tocopherol nicotinate」「benzyl nicotinate」「xantinol nicotinate」「inositol nicotinate」

「ニコチン酸」

Niacin
	IUPAC name pyridine-3-carboxylic acid
	Systematic name Pyridine-3-carboxylic acid
	Other names Bionic; Vitamin B3
Identifiers
CAS number	59-67-6
PubChem	938
ChemSpider	913
UNII	2679MF687A
EC number	200-441-0
DrugBank	DB00627
KEGG	D00049
MeSH	Niacin
ChEBI	CHEBI:15940
ChEMBL	CHEMBL573
IUPHAR ligand	1588
RTECS number	QT0525000
ATC code	C04AC01,C10AD02
Beilstein Reference	109591
Gmelin Reference	3340
3DMet	B00073
Jmol-3D images	Image 1; Image 2
	SMILES Oc(:o):c1cccnc1 OC(=O)C1=CN=CC=C1 ;
	InChI InChI=1S/C6H5NO2/c8-6(9)5-2-1-3-7-4-5/h1-4H,(H,8,9) ; Key: PVNIIMVLHYAWGP-UHFFFAOYSA-N InChI=1/C6H5NO2/c8-6(9)5-2-1-3-7-4-5/h1-4H,(H,8,9); Key: PVNIIMVLHYAWGP-UHFFFAOYAA ;
Properties
Molecular formula	C6NH5O2
Molar mass	123.1094 g mol-1
Appearance	White, translucent crystals
Density	1.473 g cm-3
Melting point	237 °C, 510 K, 458 °F
Solubility in water	18 g L-1
log P	0.219
Acidity (pKa)	2.201
Basicity (pKb)	11.796
Isoelectric point	4.75
Refractive index (nD)	1.4936
Dipole moment	0.1271305813 D
Thermochemistry
Std enthalpy of; formation ΔfHo298	-344.9 kJ mol-1
Std enthalpy of; combustion ΔcHo298	-2.73083 MJ mol-1
Pharmacology
Routes of; administration	Intramuscular, Oral
Elimination; half-life	20-45 min
Hazards
EU classification	Xi
R-phrases	R36/37/38
S-phrases	S26, S36
NFPA 704	1 1 0
Flash point	193 °C
Autoignition; temperature	365 °C
	(verify) (what is: /?); Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa)
	Infobox references

　　[★]

英: nicotinic acid nicotinate NiA
同: ナイアシン niacin、ビタミンB3、3-ピリジンカルボン酸 3-pyridinecarboxylic acid
商: ナイクリン
関: NAD、ペラグラ、ビタミン

概念

ビタミンの一つ。

ビタミンB複合体の一つで、ビタミンB3。別名、ナイアシン(和文ではニコチン酸、英文ではナイアシンという記載をよく見かける、気がする)

トリプトファンからも合成される。
高脂血症薬としても使われる

臨床関連

ナイアシン欠乏症

ペラグラを来す

参考

構造

http://fptsukioka555.blog86.fc2.com/blog-entry-14.html

wiki ja

http://ja.wikipedia.org/wiki/%E3%83%8B%E3%82%B3%E3%83%81%E3%83%B3%E9%85%B8

wiki en

http://en.wikipedia.org/wiki/%E3%83%8B%E3%82%B3%E3%83%81%E3%83%B3%E9%85%B8

「ニコチン酸塩」

　　[★]

英: nicotinate
関: ニコチン酸

「tocopherol nicotinate」

　　[★]

ニコチン酸トコフェロール

関: tocopherol、tocopherol acetate、tocopherol calcium succinate

「benzyl nicotinate」

　　[★]

ニコチン酸ベンジル、ニコチン酸ベンジルエステル

「xantinol nicotinate」

　　[★]

ニコチン酸キサンチノール

関: xanthinol niacinate

「inositol nicotinate」

　　[★]

イノシトールニコチネート

[1] "Niacin". DrugBank: a knowledgebase for drugs, drug actions and drug targets. http://www.drugbank.ca/drugs/DB00627. Retrieved 14-January-2012.

[2] "Niacin — PubChem Public Chemical Database". The PubChem Project. USA: National Center for Biotechnology Information. http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=938.

[3] Bruckert, E; Labreuche, J; Amarenco, P (2010 Jun). "Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis.". Atherosclerosis 210 (2): 353–61. doi:10.1016/j.atherosclerosis.2009.12.023. PMID 20079494.

[4] Cantarella, L., A. Gallifuoco, et al. (2011). "High-yield continuous production of nicotinic acid via nitrile hydratase-amidase cascade reactions using cascade CSMRs." Enzyme Microb Technol 48(4-5): 345-350.http://www.ncbi.nlm.nih.gov/pubmed/22112948?dopt=Citation

[5] Wan, P., S. Moat, et al. (2011). "Pellagra: a review with emphasis on photosensitivity." Br J Dermatol 164(6): 1188-1200.http://www.ncbi.nlm.nih.gov/pubmed/21128910?dopt=Citation

[6] Wan, P., S. Moat, et al. (2011). "Pellagra: a review with emphasis on photosensitivity." Br J Dermatol 164(6): 1188-1200.http://www.ncbi.nlm.nih.gov/pubmed/21128910?dopt=Citation

[7] Ishii, N. and Y. Nishihara (1981). "Pellagra among chronic alcoholics: clinical and pathological study of 20 necropsy cases." J Neurol Neurosurg Psychiatry 44(3): 209-215.http://www.ncbi.nlm.nih.gov/pubmed/7229643?dopt=Citation

[8] Jaconello P (October 1992). "Niacin versus niacinamide". CMAJ 147 (7): 990. PMC 1336277. PMID 1393911. //www.ncbi.nlm.nih.gov/pmc/articles/PMC1336277/.

[9] Knip M, Douek IF, Moore WP, et al. (2000). "Safety of high-dose nicotinamide: a review". Diabetologia 43 (11): 1337–45. doi:10.1007/s001250051536. PMID 11126400.

[isbn1-57259-153-6-10] Cox, Michael; Lehninger, Albert L; Nelson, David R. (2000). Lehninger principles of biochemistry. New York: Worth Publishers. ISBN 1-57259-153-6.

[OSU-11] Jacobson, EL (2007). "Niacin". Linus Pauling Institute. http://lpi.oregonstate.edu/infocenter/vitamins/niacin/. Retrieved 2011-08-08.

[12] Institute of Medicine (2006). Dietary Reference Intakes Research Synthesis: Workshop Summary. National Academies Press. p. 37. http://books.nap.edu/openbook.php?record_id=11767&page=37.

[13] Jacob RA, Swendseid ME, McKee RW, Fu CS, Clemens RA (April 1989). "Biochemical markers for assessment of niacin status in young men: urinary and blood levels of niacin metabolites". J. Nutr. 119 (4): 591–8. PMID 2522982. http://jn.nutrition.org/cgi/pmidlookup?view=long&pmid=2522982.

[14] Pitsavas S, Andreou C, Bascialla F, Bozikas VP, Karavatos A (2004). "Pellagra encephalopathy following B-complex vitamin treatment without niacin". Int J Psychiatry Med 34 (1): 91–5. doi:10.2190/29XV-1GG1-U17K-RGJH. PMID 15242145. http://baywood.metapress.com/link.asp?id=29xv1gg1u17krgjh.

[Prakash_581.E2.80.93584-15] Prakash, Ravi; Sachin Gandotra, Lokesh Kumar Singh, Basudeb Das, Anuja Lakra (2008). "Rapid resolution of delusional parasitosis in pellagra with niacin augmentation therapy". General Hospital Psychiatry 30 (6): 581–4. doi:10.1016/j.genhosppsych.2008.04.011. PMID 19061687. http://www.sciencedirect.com/science/article/B6T70-4T24FKB-D/2/f619871a3d1f1d626b775c84523d6d94.

[16] Altschul, R., A. Hoffer, et al. (1955). "Influence of nicotinic acid on serum cholesterol in man." Arch Biochem Biophys 54(2): 558-559.http://www.ncbi.nlm.nih.gov/pubmed/14350806?dopt=Citation

[17] Villines, T. C., A. S. Kim, et al. (2012). "Niacin: the evidence, clinical use, and future directions." Curr Atheroscler Rep 14(1): 49-59.http://www.ncbi.nlm.nih.gov/pubmed/22037771?dopt=Citation

[18] Barter, P., A. M. Gotto, et al. (2007). "HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events." N Engl J Med 357(13): 1301-1310.http://www.ncbi.nlm.nih.gov/pubmed/17898099?dopt=Citation

[19] Jafri, H., A. A. Alsheikh-Ali, et al. (2010). "Meta-analysis: statin therapy does not alter the association between low levels of high-density lipoprotein cholesterol and increased cardiovascular risk." Ann Intern Med 153(12): 800-808.http://www.ncbi.nlm.nih.gov/pubmed/21173414?dopt=Citation

[20] Wu, B. J., L. Yan, et al. (2010). "Evidence that niacin inhibits acute vascular inflammation and improves endothelial dysfunction independent of changes in plasma lipids." Arterioscler Thromb Vasc Biol 30(5): 968-975.http://www.ncbi.nlm.nih.gov/pubmed/20167660?dopt=Citation

[21] Bruckert, E., J. Labreuche, et al. (2010). "Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis." Atherosclerosis 210(2): 353-361.http://www.ncbi.nlm.nih.gov/pubmed/20079494?dopt=Citation

[22] Taylor, A. J., H. J. Lee, et al. (2006). "The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3." Curr Med Res Opin 22(11): 2243-2250.http://www.ncbi.nlm.nih.gov/pubmed/17076985?dopt=Citation

[23] Taylor, A. J., T. C. Villines, et al. (2009). "Extended-release niacin or ezetimibe and carotid intima-media thickness." N Engl J Med 361(22): 2113-2122.http://www.ncbi.nlm.nih.gov/pubmed/19915217?dopt=Citation

[24] Lukasova, M., J. Hanson, et al. (2011). "Nicotinic acid (niacin): new lipid-independent mechanisms of action and therapeutic potentials." Trends Pharmacol Sci 32(12): 700-707.http://www.ncbi.nlm.nih.gov/pubmed/21944259?dopt=Citation

[25] Lukasova, M., J. Hanson, et al. (2011). "Nicotinic acid (niacin): new lipid-independent mechanisms of action and therapeutic potentials." Trends Pharmacol Sci 32(12): 700-707.http://www.ncbi.nlm.nih.gov/pubmed/21944259?dopt=Citation

[26] Soga, T., M. Kamohara, et al. (2003). "Molecular identification of nicotinic acid receptor." Biochem Biophys Res Commun 303(1): 364-369.http://www.ncbi.nlm.nih.gov/pubmed/12646212?dopt=Citation

[27] Wise, A., S. M. Foord, et al. (2003). "Molecular identification of high and low affinity receptors for nicotinic acid." J Biol Chem 278(11): 9869-9874.http://www.ncbi.nlm.nih.gov/pubmed/12522134?dopt=Citation

[28] Gille, A., E. T. Bodor, et al. (2008). "Nicotinic acid: pharmacological effects and mechanisms of action." Annu Rev Pharmacol Toxicol 48: 79-106.http://www.ncbi.nlm.nih.gov/pubmed/17705685?dopt=Citation

[29] Wanders, D. and R. L. Judd (2011). "Future of GPR109A agonists in the treatment of dyslipidaemia." Diabetes Obes Metab 13(8): 685-691.http://www.ncbi.nlm.nih.gov/pubmed/21418500?dopt=Citation

[30] Hernandez, C., M. Molusky, et al. (2010). "Regulation of hepatic ApoC3 expression by PGC-1beta mediates hypolipidemic effect of nicotinic acid." Cell Metab 12(4): 411-419.http://www.ncbi.nlm.nih.gov/pubmed/20889132?dopt=Citation

[31] Villines, T. C., A. S. Kim, et al. (2012). "Niacin: the evidence, clinical use, and future directions." Curr Atheroscler Rep 14(1): 49-59.

[32] Rubic, T., M. Trottmann, et al. (2004). "Stimulation of CD36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin." Biochem Pharmacol 67(3): 411-419.http://www.ncbi.nlm.nih.gov/pubmed/15037193?dopt=Citation

[33] Lukasova, M., C. Malaval, et al. (2011). "Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells." J Clin Invest 121(3): 1163-1173.http://www.ncbi.nlm.nih.gov/pubmed/21317532?dopt=Citation

[34] Holzhauser, E., C. Albrecht, et al. (2011). "Nicotinic acid has anti-atherogenic and anti-inflammatory properties on advanced atherosclerotic lesions independent of its lipid-modifying capabilities." J Cardiovasc Pharmacol 57(4): 447-454.http://www.ncbi.nlm.nih.gov/pubmed/21242806?dopt=Citation

[35] Wu, B. J., L. Yan, et al. (2010). "Evidence that niacin inhibits acute vascular inflammation and improves endothelial dysfunction independent of changes in plasma lipids." Arterioscler Thromb Vasc Biol 30(5): 968-975.http://www.ncbi.nlm.nih.gov/pubmed/20167660?dopt=Citation

[36] Lukasova, M., C. Malaval, et al. (2011). "Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells." J Clin Invest 121(3): 1163-1173.http://www.ncbi.nlm.nih.gov/pubmed/21317532?dopt=Citation

[37] Benjo, A. M., R. C. Maranhao, et al. (2006). "Accumulation of chylomicron remnants and impaired vascular reactivity occur in subjects with isolated low HDL cholesterol: effects of niacin treatment." Atherosclerosis 187(1): 116-122.http://www.ncbi.nlm.nih.gov/pubmed/16458316?dopt=Citation

[38] Gustafson, B. (2010). "Adipose tissue, inflammation and atherosclerosis." J Atheroscler Thromb 17(4): 332-341.http://www.ncbi.nlm.nih.gov/pubmed/20124732?dopt=Citation

[39] Plaisance, E. P., M. Lukasova, et al. (2009). "Niacin stimulates adiponectin secretion through the GPR109A receptor." Am J Physiol Endocrinol Metab 296(3): E549-558.http://www.ncbi.nlm.nih.gov/pubmed/19141678?dopt=Citation

[40] Westphal, S. and C. Luley (2008). "Preferential increase in high-molecular weight adiponectin after niacin." Atherosclerosis 198(1): 179-183.http://www.ncbi.nlm.nih.gov/pubmed/17996241?dopt=Citation

[41] Digby, J. E., E. McNeill, et al. (2010). "Anti-inflammatory effects of nicotinic acid in adipocytes demonstrated by suppression of fractalkine, RANTES, and MCP-1 and upregulation of adiponectin." Atherosclerosis 209(1): 89-95.http://www.ncbi.nlm.nih.gov/pubmed/19781706?dopt=Citation

[42] JAMA. (1975). "Clofibrate and niacin in coronary heart disease." JAMA 231(4): 360-381.

[43] Bruckert, E., J. Labreuche, et al. (2010). "Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis." Atherosclerosis 210(2): 353-361.http://www.ncbi.nlm.nih.gov/pubmed/20079494?dopt=Citation

[44] Duggal, J. K., M. Singh, et al. (2010). "Effect of niacin therapy on cardiovascular outcomes in patients with coronary artery disease." J Cardiovasc Pharmacol Ther 15(2): 158-166.http://www.ncbi.nlm.nih.gov/pubmed/20208032?dopt=Citation

[45] NCEP. (2002). "Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report." Circulation 106(25): 3143-3421.

[46] H., P. Alagona, et al. (1998). "Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia." Metabolism 47(9): 1097-1104.http://www.ncbi.nlm.nih.gov/pubmed/9751239?dopt=Citation

[47] Bays, H., A. Shah, et al. (2011). "Extended-release niacin/laropiprant lipid-altering consistency across patient subgroups." Int J Clin Pract 65(4): 436-445.http://www.ncbi.nlm.nih.gov/pubmed/21401833?dopt=Citation

[48] McKenney, J., H. Bays, et al. (2010). "Safety of extended-release niacin/laropiprant in patients with dyslipidemia." J Clin Lipidol 4(2): 105-112 e101.http://www.ncbi.nlm.nih.gov/pubmed/21122637?dopt=Citation

[pmid17705685-49] Gille A, Bodor ET, Ahmed K, Offermanns S (2008). "Nicotinic acid: pharmacological effects and mechanism of action". Annu Rev Pharmacol Toxicol 48: 79–106. doi:10.1146/annurev.pharmtox.48.113006.094746. PMID 17705685.

[Katzung-50] Katzung, Bertram G. (2006). Basic and clinical pharmacology. New York: McGraw-Hill Medical Publishing Division. ISBN 0-07-145153-6. http://www.medicinenet.com/niacin/article.htm.

[pmid15842130-51] McGovern ME (2005). "Taking aim at HDL-C. Raising levels to reduce cardiovascular risk". Postgrad Med 117 (4): 29–30, 33–5, 39 passim. doi:10.3810/pgm.2005.04.1610. PMID 15842130.

[pmid3782631-52] Canner PL, Berge KG, Wenger NK, et al. (1986). "Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin". J. Am. Coll. Cardiol. 8 (6): 1245–55. doi:10.1016/S0735-1097(86)80293-5. PMID 3782631.

[53] Taylor AJ, Villines TC, Stanek EJ, et al. (November 2009). "Extended-release niacin or ezetimibe and carotid intima-media thickness". N. Engl. J. Med. 361 (22): 2113–22. doi:10.1056/NEJMoa0907569. PMID 19915217.

[54] Singer, Natasha (November 15, 2009). "Study Raises Questions About Cholesterol Drug’s Benefit". The New York Times. Retrieved November 16, 2009.

[55] Bruckert, E; Labreuche, J; Amarenco, P (2010). "Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis". Atherosclerosis 210 (2): 353–61. doi:10.1016/j.atherosclerosis.2009.12.023. PMID 20079494.

[56] Aim-High, I.; Boden, W. E.; Probstfield, J. L.; Anderson, T.; Chaitman, B. R.; Desvignes-Nickens, P.; Koprowicz, K.; McBride, R. et al. (2011). "Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy". New England Journal of Medicine 365 (24): 2255–2267. doi:10.1056/NEJMoa1107579. PMID 22085343. edit

[57] Lai, E., I. De Lepeleire, et al. (2007). "Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D2 receptor subtype 1." Clin Pharmacol Ther 81(6): 849-857.http://www.ncbi.nlm.nih.gov/pubmed/17392721?dopt=Citation

[58] Kamanna, V. S., A. Vo, et al. (2008). "Nicotinic acid: recent developments." Curr Opin Cardiol 23(4): 393-398.http://www.ncbi.nlm.nih.gov/pubmed/18520725?dopt=Citation.

[59] Villines, T. C., A. S. Kim, et al. (2012). "Niacin: the evidence, clinical use, and future directions." Curr Atheroscler Rep 14(1): 49-59.http://www.ncbi.nlm.nih.gov/pubmed/22037771?dopt=Citation

[60] Norris, R. B. (2006). ""Flush-free niacin": dietary supplement may be "benefit-free"." Prev Cardiol 9(1): 64-65.http://www.ncbi.nlm.nih.gov/pubmed/16407706?dopt=Citation

[61] Villines, T. C., A. S. Kim, et al. (2012). "Niacin: the evidence, clinical use, and future directions." Curr Atheroscler Rep 14(1): 49-59.http://www.ncbi.nlm.nih.gov/pubmed/22037771?dopt=Citation

[G.26G-62] Keith Parker; Laurence Brunton; Goodman, Louis Sanford; Lazo, John S.; Gilman, Alfred (2006). Goodman & Gilman's the pharmacological basis of therapeutics. New York: McGraw-Hill. ISBN 0-07-142280-3.

[63] Benyo, Z., A. Gille, et al. (2005). "GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing." J Clin Invest 115(12): 3634-3640.http://www.ncbi.nlm.nih.gov/pubmed/16322797?dopt=Citation

[64] Benyo, Z., A. Gille, et al. (2006). "Nicotinic acid-induced flushing is mediated by activation of epidermal langerhans cells." Mol Pharmacol 70(6): 1844-1849.http://www.ncbi.nlm.nih.gov/pubmed/17008386?dopt=Citation

[65] Hanson, J., A. Gille, et al. (2010). "Nicotinic acid- and monomethyl fumarate-induced flushing involves GPR109A expressed by keratinocytes and COX-2-dependent prostanoid formation in mice." J Clin Invest 120(8): 2910-2919.http://www.ncbi.nlm.nih.gov/pubmed/20664170?dopt=Citation

[66] Maciejewski-Lenoir, D., J. G. Richman, et al. (2006). "Langerhans cells release prostaglandin D2 in response to nicotinic acid." J Invest Dermatol 126(12): 2637-2646.http://www.ncbi.nlm.nih.gov/pubmed/17008871?dopt=Citation

[67] Kamanna, V. S. and M. L. Kashyap (2008). "Mechanism of action of niacin." Am J Cardiol 101(8A): 20B-26B. Nicotinic acid (niacin) has long been used for the treatment of lipid disorders and cardiovascular http://www.ncbi.nlm.nih.gov/pubmed/18375237?dopt=Citation

[68] "Guidelines for Niacin Therapy For the Treatment of Elevated Lipoprotein a (Lpa)". Rush Hemophilia & Thrombophilia Center. August 15, 2002, Revised July 27, 2005. http://www.rush.edu/Rush_Document/Niacin%20therapy%20for%20elevated%20Lpa,0.pdf. Retrieved 20 November 2009. "facial flushing is a common side effect of niacin therapy that usually subsides after several weeks of consistent niacin use"

[69] Barter, P (2006). "Options for therapeutic intervention: How effective are the different agents?". European Heart Journal Supplements 8 (F): F47–F53. doi:10.1093/eurheartj/sul041.

[pmid15324528-70] Chapman MJ, Assmann G, Fruchart JC, Shepherd J, Sirtori C (2004). "Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid—a position paper developed by the European Consensus Panel on HDL-C". Curr Med Res Opin 20 (8): 1253–68. doi:10.1185/030079904125004402. PMID 15324528.

[ReferenceA-71] Papaliodis D, Boucher W, Kempuraj D, Michaelian M, Wolfberg A, House M, Theoharides TC (December 2008). "Niacin-induced "Flush" Involves Release of Prostaglandin D2 from Mast Cells and Serotonin from Platelets: Evidence from Human Cells in Vitro and an Animal Model". J Pharmacol Exp Ther 327 (3): 665–72. doi:10.1124/jpet.108.141333. PMID 18784348. http://jpet.aspetjournals.org/cgi/pmidlookup?view=long&pmid=18784348.

[72] Gille, A., E. T. Bodor, et al. (2008). "Nicotinic acid: pharmacological effects and mechanisms of action." Annu Rev Pharmacol Toxicol 48: 79-106.http://www.ncbi.nlm.nih.gov/pubmed/17705685?dopt=Citation

[pmid11122726-73] Capuzzi DM, Morgan JM, Brusco OA, Intenzo CM (2000). "Niacin dosing: relationship to benefits and adverse effects". Curr Atheroscler Rep 2 (1): 64–71. doi:10.1007/s11883-000-0096-y. PMID 11122726.

[pmid17418450-74] Mittal MK, Florin T, Perrone J, Delgado JH, Osterhoudt KC (2007). "Toxicity from the use of niacin to beat urine drug screening". Ann Emerg Med 50 (5): 587–90. doi:10.1016/j.annemergmed.2007.01.014. PMID 17418450.

[pmid15035390-75] Gass JD (2003). "Nicotinic acid maculopathy. 1973". Retina (Philadelphia, Pa.) 23 (6 Suppl): 500–10. PMID 15035390.

[efsa.europa.eu-76] ttp://www.efsa.europa.eu/en/scdocs/doc/ans_ej949_Inositol_hexanicotinate_op_en_REV.pdf

[77] Taheri, R (2003-01-15). "No-Flush Niacin for the Treatment of Hyperlipidemia". Medscape. http://www.medscape.com/viewarticle/447528. Retrieved 2008-03-31.

[78] Kruse W, Kruse W, Raetzer H, Heuck CC, Oster P, Schellenberg B, Schlierf G (1979). "Nocturnal inhibition of lipolysis in man by nicotinic acid and derivatives". European Journal of Clinical Pharmacology 16 (1): 11–15. doi:10.1007/BF00644960. PMID 499296.

[79] Meyers CD, Carr MC, Park S, Brunzell JD (2003). "Varying cost and free nicotinic acid content in over-the-counter niacin preparations for dyslipidemia". Annals of Internal Medicine 139 (12): 996–1002. doi:10.7326/0003-4819-139-12-200312160-00009. PMID 14678919. http://www.annals.org/content/139/12/996.full.pdf+html.

[80] Benjó AM, Maranhão RC, Coimbra SR, Andrade AC, Favarato D, Molina MS, Brandizzi LI, da Luz PL (2006). "Accumulation of chylomicron remnants and impaired vascular reactivity occur in subjects with isolated low HDL cholesterol: effects of niacin treatment". Atherosclerosis 187 (1): 116–122. doi:10.1016/j.atherosclerosis.2005.08.025. PMID 16458316.

[pmid16018973-81] Zhang Y, Schmidt RJ, Foxworthy P, et al. (2005). "Niacin mediates lipolysis in adipose tissue through its G-protein coupled receptor HM74A". Biochem. Biophys. Res. Commun. 334 (2): 729–32. doi:10.1016/j.bbrc.2005.06.141. PMID 16018973.

[pmid15580557-82] Zellner C, Pullinger CR, Aouizerat BE, et al. (2005). "Variations in human HM74 (GPR109B) and HM74A (GPR109A) niacin receptors". Hum. Mutat. 25 (1): 18–21. doi:10.1002/humu.20121. PMID 15580557.

[83] "Food Data Chart - Niacin". http://www.healthyeatingclub.com/info/books-phds/books/foodfacts/html/data/data4c.html. Retrieved 7 September 2012.

[84] Weidel, H (1873). "Zur Kenntniss des Nicotins". Justus Liebig's Annalen der Chemie und Pharmacie 165 (2): 330–349. doi:10.1002/jlac.18731650212.

[85] Samuel M. McElvain (1941), "Nicotinic Acid", Org. Synth., http://www.orgsyn.org/orgsyn/orgsyn/prepContent.asp?prep=CV1P0385.pdf; Coll. Vol. 1: 385

[Elvehjem-86] Elvehjem CA, Madden RJ, Strongandd FM, Woolley DW (1938). "The isolation and identification of the anti-blacktongue factor J" (PDF). J. Biol. Chem. 123 (1): 137–149. http://www.jbc.org/content/123/1/137.full.pdf.

[87] Dr. Joseph Goldberger and the war on Pellagra - Office of NIH History

[pmid14880960-88] LAGUNA J, CARPENTER KJ (September 1951). "Raw versus processed corn in niacin-deficient diets". J. Nutr. 45 (1): 21–8. PMID 14880960. http://jn.nutrition.org/cgi/pmidlookup?view=long&pmid=14880960.

[UMM-89] "Vitamin B3". University of Maryland Medical Center. 2002-01-04. http://www.umm.edu/altmed/articles/vitamin-b3-000335.htm. Retrieved 2008-03-31.

[90] Paolini JF, Bays HE, Ballantyne CM, et al. (November 2008). "Extended-release niacin/laropiprant: reducing niacin-induced flushing to better realize the benefit of niacin in improving cardiovascular risk factors". Cardiol Clin 26 (4): 547–60. doi:10.1016/j.ccl.2008.06.007. PMID 19031552.

匿名

検索

案内

案内

nicotinate